News

AMW GmbH realigns management

Dr. Wilfried Fischer, founding shareholder of AMW, has retired from the management board and remains associated with the company as an important shareholder. His areas of responsibility will be taken over by the previous Co-Managing Directors Dr. Friedrich Tegel and Philipp Karbach.

read more

AMW GmbH from Warngau continues to grow and founds an advisory board

Meanwhile more than 100 employees are employed at the pharmaceutical companyin Warngau. The specialy pharmaceuticalwas able to develop a generic drug for the contraception ring Nuvaring of MSD to market maturityin addition to the implants Goserelin and Leuprorelin as well as patches Buprenorphin and Rivastigmin,. With this product, AMW is setting new standards in contraception. Furthermorenew products are under development. In order to position itself even better scientifically and technically, AMW founds an advisory board consisting of Dr. Georg Ingram, Dr. Dirk Schrader and Prof. Dr. Gerhard Winter.

read more

Brussels, 21 December 2017: Investment Plan for Europe: EIB lends to AMW GmbH in Warngau

The European Investment Bank (EIB) is providing EUR 25 million to AMW GmbH (AMW). AMW is a specialist pharmaceutical company that specializes in novel drug delivery systems. With the money, AMW will be able to expand the development of innovative medicines, carry out clinical trials and expand its production capacity at its plant in Warngau in Upper Bavaria as well as at its subsidiary Endomedica (Halle, Saxony-Anhalt). A new building for research, development and production with special manufacturing technology and state-of-the-art laboratory equipment is to be built at the company headquarters in Warngau.

read more

Endomedica GmbH, our wholly owned subsidiary based in Halle, was able to present itself to a wide audience including well-known pharmaceutical companies and investors from the fields of biotechnology and medical technology at the Health Innovation Summit on 11.7.2017.

The event took place simultaneously as a webinar in Munich, Tokyo and Silicon Valley and allowed discussion rounds after the presentation.

read more

On 22 June 2017, the AMW received a high visit from the Bavarian Minister of Economic Affairs and Deputy Prime Minister of the Free State of Bavaria.

Within this framework, the pharmaceutical plant was able to present itself as the largest training company in Warngau.

read more

Specialty pharmaceutical company AMW is making great steps

Warngau – AMW GmbH, founded in 2008 and based in Warngau south of Munich, is a dynamically growing specialty pharmaceutical company with bright prospects. The company develops and sells transdermal systems, i.e. active ingredients that enter the body through the skin, as well as implants loaded with highly effective active ingredients, which release their active ingredient to the body evenly over months and thereby dissolve completely. The AMW is supported by well-known investors. In a recent financing round to finance growth, investors reaffirmed their commitment to AMW and brought in around another six million euros.

read more